Galderma Laboratories, L.P. v. Tolmar, Inc., No. 13-1034 (Fed. Cir. Dec. 11, 2013)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

In this patent infringement case, Tolmar, Inc. cha l- lenges the district court’s holding that the claims of U.S. Patent Nos. 7,579,377 ( ’377 patent) ; 7,737,181 ( ’181 patent); 7,834,060 ( ’060 patent) ; 7,838,558 ( ’558 patent) ; and 7,868,044 (’044 patent), which are owned by Galde r- ma Laboratories, L.P., Galderma S.A., and Galderma Research and Development, S.N.C. (collectively, “ Galder- ma”) are not invalid under 35 U.S.C. § 103. We find that the district court erred in finding the claims of the assert- ed patents not invalid as obvious.